3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Genitourinary
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
69
Breast Neoplasms
51
Carcinoma, Non-Small-Cell Lung
29
Neoplasms
27
Myelodysplastic Syndromes
27
Advanced Solid Tumors
27
Advanced Solid Tumor
26
Prostatic Neoplasms
23
Stomach Neoplasms
19
Recurrence
19
Multiple Myeloma
19
Neoplasm Metastasis
18
Carcinoma, Hepatocellular
17
Lung Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
14
Uterine Cervical Neoplasms
13
Solid Tumor
13
Sarcoma
13
Melanoma
13
Leukemia, Myelomonocytic, Chronic
13
Colorectal Neoplasms
12
Triple Negative Breast Neoplasms
10
Small Cell Lung Carcinoma
10
Lymphoma, Large B-Cell, Diffuse
10
Esophageal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
7
Interventions
Fluorouracil
267
Oxaliplatin
266
Capecitabine
225
Leucovorin
209
Irinotecan
151
Radiotherapy
132
Bevacizumab
112
Cetuximab
81
Folfox protocol
49
Surgical Procedures, Operative
44
Radiation
41
Drug Therapy
41
Neoadjuvant Therapy
40
Chemoradiotherapy
33
Chemotherapy, Adjuvant
32
Panitumumab
27
XELOX
25
Magnetic Resonance Spectroscopy
22
Radiotherapy, Intensity-Modulated
21
Floxuridine
17
Biopsy
16
Nivolumab
15
Gemcitabine
15
Early Intervention, Educational
15
pembrolizumab
14
Laparoscopy
14
IFL protocol
14
Celecoxib
14
trifluridine tipiracil drug combination
13
Gene Expression Profiling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled
NCT02584400
2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2
Terminated
1 enrolled